User:Mr. Ibrahem/Eptinezumab

Eptinezumab, sold under the brand name Vyepti, is a medication used to prevent migraines in adults. It is used in those who have at least four migraines per month. It is given by gradual injection into a vein.

Common side effects include runny nose and allergic reactions. While there is no evidence of harm in pregnancy, such use has not been well studied. It is a monoclonal antibody that blocks calcitonin gene-related peptides (CGRP).

Eptinezumab was approved for medical use in the United States in 2020 and Europe and the United Kingdom in 2022. In the United States it costs about 1,700 USD per dose as of 2022. It is being studied in cluster headaches.